Physician profile
Jacquelyn Hunter
NPI 1629639406
$2,352.83
in general payments reported to CMS, 2019-2025
14 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $168 · 2023: $343 · 2024: $96.69 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,184.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $818.72 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $420.88 | 2023-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $376.22 | 2024-2025 | Nucala |
| Galderma Laboratories, L.P. | $128.19 | 2025 | Nemluvio |
| Amgen INC. | $122.78 | 2023 | Tezspire |
| Biocryst US Sales Co., LLC | $108.62 | 2024-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $81.45 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $71.25 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $64.30 | 2025 | Dawnzera |
| Grifols USA, LLC | $49.96 | 2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $41.77 | 2025 | Cuvitru |
| Optinose US, INC. | $33.74 | 2025 | |
| Chiesi USA, INC. | $18.25 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.70 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.